Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 12/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.37 |
| ▸ | CALCRL | Q16602 | 3/20 | 0.36 |
| ▸ | RAMP1 | O60894 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.35 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.35 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14084931 | 1.00 | BDKRB1 (0.45) | BDKRB1CCNA2CDK2CCNA1CALCRL | |
| SCHEMBL14084917 | 0.91 | BDKRB1 (0.47) | BDKRB1CCNA2CDK2CCNA1MEN1 | |
| SCHEMBL6046004 | 0.91 | BDKRB1 (0.47) | BDKRB1CCNA2CDK2CCNA1MEN1 | |
| SCHEMBL14084893 | 0.90 | BDKRB1 (0.48) | BDKRB1CCNA2CDK2CCNA1CALCRL | |
| SCHEMBL4705740 | 0.90 | BDKRB1 (0.41) | BDKRB1CCNA2CDK2CCNA1CALCRL | |
| SCHEMBL6045900 | 0.88 | BDKRB1 (0.46) | BDKRB1CCNA2CDK2CCNA1CALCRL | |
| SCHEMBL14084892 | 0.87 | BDKRB1 (0.47) | BDKRB1CCNA2CDK2CCNA1CALCRL | |
| SCHEMBL14084921 | 0.87 | BDKRB1 (0.47) | BDKRB1CCNA2CDK2CCNA1CALCRL | |
| SCHEMBL14084872 | 0.87 | BDKRB1 (0.50) | BDKRB1CCNA2CDK2CCNA1MEN1 | |
| SCHEMBL14084871 | 0.87 | BDKRB1 (0.50) | BDKRB1CCNA2CDK2CCNA1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060281733-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. | 2006-12-14 | — | — | US | claimed |
| US-20060281733-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281733-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | BDKRB1, BDKRB2, CNR1 | BDKRB1 1/4885CCNA2 691/4885CDK2 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.